US Patent Issued to Bristol-Myers Squibb on March 31 for "Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody" (New Jersey Inventor)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,153, issued on March 31, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody" was invented by Arvin Yang (Princeton, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 m...